HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Tadalafil: novel aspects of phosphodiesterase-5 inhibition in the treatment of pulmonary hypertension].

Abstract
Tadalafil, which was commercialized in 2009, is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor, and may be a safe and effective therapeutic alternative for patients with class II and III pulmonary hypertension (PH) in the World Health Organization's classification--as stated in the Clinical Practice Guidelines for the Diagnosis and Treatment of PH of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS)--providing benefits in exercise tolerance, delaying clinical deterioration and improving quality of life. Given the greater half-life of this drug, allowing a single oral dose of 40 mg per day, tadalafil could improve therapeutic compliance--thus facilitating treatment adherence--among patients with PH.
AuthorsJavier Gaudó Navarro, Antonio Sueiro Bendito
JournalArchivos de bronconeumologia (Arch Bronconeumol) Vol. 47 Suppl 7 Pg. 26-31 ( 2011) ISSN: 1579-2129 [Electronic] Spain
Vernacular TitleTadalafilo: nuevos aspectos de la inhibición de la fosfodiesterasa tipo 5 en el tratamiento de la hipertensión pulmonar.
PMID23351473 (Publication Type: English Abstract, Journal Article, Review)
CopyrightCopyright © 2011 Sociedad Española de Neumología y Cirugía Torácica. Published by Elsevier Espana. All rights reserved.
Chemical References
  • Carbolines
  • Phosphodiesterase 5 Inhibitors
  • Tadalafil
  • Cyclic Nucleotide Phosphodiesterases, Type 5
  • Cyclic GMP
Topics
  • Carbolines (adverse effects, pharmacology, therapeutic use)
  • Cyclic GMP (metabolism)
  • Cyclic Nucleotide Phosphodiesterases, Type 5 (physiology)
  • Double-Blind Method
  • Drug Interactions
  • Exercise Tolerance (drug effects)
  • Humans
  • Hypertension, Pulmonary (drug therapy, enzymology)
  • Molecular Structure
  • Phosphodiesterase 5 Inhibitors (adverse effects, pharmacology, therapeutic use)
  • Prognosis
  • Quality of Life
  • Randomized Controlled Trials as Topic
  • Second Messenger Systems
  • Tadalafil

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: